The SLC16 Family Of Monocarboxylate Transporter pipeline drugs market research report outlays comprehensive information on the SLC16 Family Of Monocarboxylate Transporter targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the SLC16 Family Of Monocarboxylate Transporter pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, and Metabolic Disorders which include the indications Unspecified Cancer, Oncology, Autoimmune Disorders, and Unspecified Metabolic Disorders. It also reviews key players involved in SLC16 Family Of Monocarboxylate Transporter targeted therapeutics development with respective active and dormant or discontinued products.
The SLC16 Family Of Monocarboxylate Transporter pipeline targets constitutes close to seven molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 2, and 3 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 1 molecule.
SLC16 Family Of Monocarboxylate Transporter overview
The SLC16 family, also known as the monocarboxylate transporter (MCT) family, is a group of membrane transport proteins that facilitate the transport of monocarboxylates across cell membranes. Monocarboxylates include molecules such as lactate, pyruvate, and certain ketone bodies. The SLC16 family is involved in various physiological processes, including energy metabolism, pH regulation, and cellular signaling. The SLC16 family consists of multiple subtypes, including MCT1 (SLC16A1), MCT2 (SLC16A7), MCT3 (SLC16A8), and MCT4 (SLC16A3), among others. Dysregulation of MCT expression and function has been associated with various pathological conditions, including cancer, neurodegenerative diseases, and metabolic disorders.
For a complete picture of SLC16 Family Of Monocarboxylate Transporter’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
